Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

(2013) E. I. Zimmerman et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacology of Axitinib

(2013) Ying Chen et al.   CLINICAL PHARMACOKINETICS

Cytochrome P450-3A Phenotyping Using Midazolam Is Not Altered by OATP1B1 Polymorphisms

(2013) V C Ziesenitz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer

(2012) Jonas Bergh et al.   BREAST

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

(2012) L P Martin et al.   BRITISH JOURNAL OF CANCER

Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice

(2012) E. van de Steeg et al.   CLINICAL CANCER RESEARCH

Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

(2012) A.-J. M. de Graan et al.   CLINICAL CANCER RESEARCH

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

(2012) C S Lancaster et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

579 Phase I and Pharmacokinetic (PK) Study of Pazopanib in Combination with Two Schedules of Docetaxel (D) in Patients (pts) with Advanced Solid Tumors

(2012) P. Hamberg et al.   EUROPEAN JOURNAL OF CANCER

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours

(2012) Ahmad Awada et al.   EUROPEAN JOURNAL OF CANCER

Pharmaceutical Excipients Influence the Function of Human Uptake Transporting Proteins

(2012) Anett Engel et al.   MOLECULAR PHARMACEUTICS

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer

(2011) Roisin M. Connolly et al.   BREAST CANCER RESEARCH AND TREATMENT

OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies

(2011) Megan Roth et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

(2011) Keith T. Flaherty et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1'-Hydroxylation

(2011) M. Sugiyama et al.   DRUG METABOLISM AND DISPOSITION

Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia

(2011) Shuiying Hu et al.   JNCI-Journal of the National Cancer Institute

Humanized mice with ectopic artificial liver tissues

(2011) A. A. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functions of OATP1A and 1B transporters in vivo: insights from mouse models

(2011) Dilek Iusuf et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

(2010) C-F Xu et al.   BRITISH JOURNAL OF CANCER

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

(2010) B C Goh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

(2010) A. R. Tan et al.   ONCOLOGIST

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

(2009) Isamu Okamoto et al.   INVESTIGATIONAL NEW DRUGS

Species Difference in the Effect of Grapefruit Juice on Intestinal Absorption of Talinolol between Human and Rat

(2009) Y. Shirasaka et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies

(2008) E. G. Chiorean et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

(2008) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer

(2008) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY